FDA's Biosimilars Meeting Management Should Improve After Reorg In New Drug Office
Executive Summary
US FDA met more biosimilar user fee program meeting performance goals in FY 2018 compared to prior year but still fell short in scheduling for three of five types of meetings. Office of New Drugs reorganization, once completed, should address some logistical scheduling issues.
You may also be interested in...
Curious Biosimilar Issues: More Workload, But Fewer US FDA Staff Needed
The US FDA’s capacity planning formula indicates a smaller biosimilar program than a year ago, but says supplement, meeting and other work continue to increase.
Curious Biosimilar Issues: More Workload, But Fewer US FDA Staff Needed
The US FDA’s capacity planning formula indicates a smaller biosimilar program than a year ago, but says supplement, meeting and other work continue to increase.
US Biosimilars Will Get Regulatory Science Program, Supplement Timeline Changes In Next User Fee Agreement
Talks are completed, leaving only the generic drug user fee reauthorization negotiations ongoing.